Company news

Aprea Therapeutics, Inc. news in 2025

Aprea Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

December 18, 2025

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 9, 2025

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

November 12, 2025

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

October 24, 2025

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

October 15, 2025

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

August 28, 2025

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

August 12, 2025

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

June 25, 2025

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

May 14, 2025

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

March 31, 2025

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 25, 2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

March 11, 2025

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

February 4, 2025

Decks in 2025